Ignite Creation Date:
2025-12-26 @ 10:57 AM
Ignite Modification Date:
2026-02-25 @ 1:54 AM
Study NCT ID:
NCT02611908
Status:
WITHDRAWN
Last Update Posted:
2019-01-25
First Post:
2015-11-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
Sponsor:
Michael Choi
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-06
Start Date Type:
None
Primary Completion Date:
2019-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2020-11
Completion Date Type:
ESTIMATED
First Submit Date:
2015-11-19
First Submit QC Date:
None
Study First Post Date:
2015-11-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-01-23
Last Update Post Date:
2019-01-25
Last Update Post Date Type:
ACTUAL